Comparative Pharmacology
Head-to-head clinical analysis: KARIVA versus NORINYL 1 50 21 DAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KARIVA versus NORINYL 1 50 21 DAY.
KARIVA vs NORINYL 1+50 21-DAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol (estrogen) and levonorgestrel (progestin) that inhibits gonadotropin release, suppressing ovulation, altering cervical mucus to impede sperm penetration, and changing endometrial receptivity.
Norinyl 1+50 21-Day contains norethindrone (a progestin) and mestranol (an estrogen). Mestranol is converted to ethinyl estradiol, which provides negative feedback on gonadotropin release, inhibiting ovulation. Norethindrone suppresses gonadotropins and alters cervical mucus and endometrial lining to prevent implantation.
One tablet (0.15 mg levonorgestrel/0.03 mg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by 7 days of placebo.
One tablet (1 mg norethindrone + 0.05 mg mestranol) orally once daily for 21 days, followed by 7 placebo tablets. Start on day 1 of menstrual cycle or first Sunday after onset.
None Documented
None Documented
Terminal elimination half-life is 4.5 hours; in renal impairment (CrCl <30 mL/min), half-life may extend to 8-10 hours, requiring dose adjustment.
Norethindrone: 5-8 hours; Ethinyl estradiol: 7-15 hours; steady-state reached within 5-7 days
Approximately 55% renal (30% as unchanged drug, 25% as metabolites) and 45% fecal (via biliary elimination).
Renal (40% as metabolites), fecal (50% as metabolites), <1% unchanged
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive